15 November 2018
EMA/759832/2018
EMEA/H/C/001245

Public statement

Trobalt

Withdrawal of the marketing authorisation in the European Union

On 19 July 2018, the European Commission withdrew the marketing authorisation for Trobalt (retigabine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Glaxo Group Ltd, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Trobalt was granted marketing authorisation in the EU on 28 March 2011 for adjunctive treatment of partial onset seizures. The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2016.

The European Public Assessment Report (EPAR) for Trobalt will be updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact